Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26271067.
- Also identified by DOI 10.1016/j.jacc.2015.05.053.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The duration of dual antiplatelet therapy (DAPT) after coronary stenting has been evaluated in randomized studies with apparently conflicting results. Although longer exposure associates with more bleeding complications, late stent thrombosis (ST) and myocardial infarction are reduced. In addition, as new drug-eluting stents carry a lower risk of ST compared with the first-generation drug-eluting stents and possibly even bare-metal stents, a shift toward better protection from ST may have an effect on the duration and intensity of DAPT. Whether the duration of DAPT should be shorter or longer than the currently recommended 6 to 12 months is analyzed in this review, drawing on lessons from the most recent studies.
Medical subject headings
- Drug-Eluting Stents
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists